Organon BioSciences appoints Joost Helsen as General Manager of Nobilon
Joost Helsen has been appointed General Manager of Nobilon, the human vaccines business of Organon BioSciences. Nobilon is a key strategic initiative, founded in 2002, that bridges Intervet's expertise in vaccine development with Organon's ability to register and market human health care products.
Joost Helsen (48) joined Organon in 1985. After having served in various financial functions within Organon and Akzo Nobel, he joined Intervet in 1995 as controller. Mr. Helsen will have a pivotal role in the execution of the overall Organon BioSciences biotechnology strategy. Since 2003, Mr. Helsen has been responsible for manufacturing and logistics at Intervet International and has been a Member of the Executive Committee of Intervet.
Nobilon intends to become a fully integrated biotechnology company encompassing research, development, registration, production and commercialization of selected vaccines. The cost efficient production of vaccines through cell culture shall serve as a platform for Nobilon to build a strong position in the areas of influenza and other respiratory vaccine development. The Nobilon facility received European approval last year to manufacture both animal and human vaccines.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
